Owner with no medical background designs mRNA vaccine for dog's cancer

An Australian tech entrepreneur used AI tools to help design a personalized mRNA vaccine for his dog, which a university lab manufactured and which the owner says reduced the tumor burden by about 75% and improved the dog's mobility.

An Australian tech entrepreneur used artificial intelligence tools to help design a personalized mRNA cancer vaccine for his 8-year-old rescue dog, Rose. The owner has no formal medical training but has experience in machine learning and data analysis. The RNA Institute at the University of New South Wales manufactured the vaccine from the sequence the owner provided. After vaccination, the owner reported marked improvement in Rose's mobility and a substantial reduction in the tumor burden. Key details: - The owner used AI-assisted analysis of the tumor to identify targets for a personalized mRNA construct. - The RNA Institute at UNSW produced the vaccine and delivered the construct in under two months after receiving the designed sequence. - The owner reported the vaccine reduced about 75 percent of the cancer and that Rose's mobility and behavior improved within a month. - Researchers involved are examining tissue from the portion of the tumor that did not respond to explore possible next steps. Summary: Reported as a rapid, bespoke application of AI and mRNA technology in a single veterinary case, the intervention is described by the owner and the university team as having reduced much of the tumor and improved the dog's condition. Undetermined at this time.